Abstract:Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and leads to ~10,000 deaths each year. Nifurtimox and benznidazole are the only two drugs available but have significant adverse effects and limited efficacy. New chemotherapeutic agents are urgently required. Here we identified inhibitors of the acidic M17 leucyl-aminopeptidase from T . cruzi (LAPTc) that show promise as novel starting points for Chagas disease drug discovery. A RapidFire-MS screen with a protease-focused compound library identified novel LAPTc inhibitors. Twenty-eight hits were progressed to the dose-response studies, from which 12 molecules inhibited LAPTc with IC 50 < 34 μM. Of these, compound 4 was the most potent hit and mode of inhibition studies indicate that compound 4 is a competitive LAPTc inhibitor, with K i 0.27 μM. Compound 4 is selective with respect to human LAP3, showing a selectivity index of >500. Compound 4 exhibited sub-micromolar activity against intracellular T . cruzi amastigotes, and while the selectivity-window against the host cells was narrow, no toxicity was observed for un-infected HepG2 cells. In silico modelling of the LAPTc-compound 4 interaction is consistent with the competitive mode of inhibition. Molecular dynamics simulations reproduce the experimental binding strength (-8.95 kcal/mol), and indicate a binding mode based mainly on hydrophobic interactions with active site residues without metal cation coordination. Our data indicates that these new LAPTc inhibitors should be considered for further development as antiparasitic agents for the treatment of Chagas disease. Trypanosoma cruzi is a single cell eukaryotic parasite that infects humans and animals. Infection can result in Chagas disease, a debilitating chronic disease that frequently affects the heart. The major downside of the current treatments is their side-effects, which frequently prevent patients from completing their treatment course. New, safer medicines are therefore urgently needed. Here we sought to enable the development of new medicines by identifying inhibitors of a key parasite enzyme; acidic M17 leucyl-aminopeptidase (LAPTc). We identified 28 LAPTc inhibitors, among more than 3000 compounds tested. The most potent inhibitor, compound 4, inhibited parasite growth and did not inhibit the equivalent human aminopeptidase. Using computational tools, we predicted how this compound binds to the enzyme. Our results indicate that the LAPTc inhibitors could be considered for further development as antiparasitic agents for the treatment of Chagas disease.

Structural analysis and shape-based identification of novel inhibitors targeting the Trypanosoma cruzi proteasome

Cascade Ligand- and Structure-Based Virtual Screening to Identify New Trypanocidal Compounds Inhibiting Putrescine Uptake

Structural investigation of Trypanosoma cruzi Akt-like kinase as drug target against Chagas disease

Repositioning FDA-Approved Drug Against Chagas Disease and Cutaneous Leishmaniosis by Structure-Based Virtual Screening

Structure–activity relationships of novel N-imidazoylpiperazines with potent anti-Trypanosoma cruzi activity

Structure-Aided Computational Design of Triazole-Based Targeted Covalent Inhibitors of Cruzipain

A Computational Approach Using α-Carbonic Anhydrase to Find Anti-Trypanosoma cruzi Agents

Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease

Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease.

Hit-to-lead optimization of novel benzimidazole phenylacetamides as broad spectrum trypanosomacides

Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery

Optimization of benzenesulfonyl derivatives as anti- Trypanosomatidae agents: Structural design, synthesis, and pharmacological assessment against Trypanosoma cruzi and Leishmania infantum

Discovery of Strong 3-Nitro-2-Phenyl- 2H-Chromene Analogues as Antitrypanosomal Agents and Inhibitors of Trypanosoma cruzi Glucokinase

Pt(II) and Pd(II) complexes with coumarin-thiosemicarbazone hybrid ligands and triphenylphosphine coligand as potential anti T. cruzi agents

Nanomolar Activity of Coumarin-3-thiosemicarbazones Targeting Trypanosoma cruzi Cruzain and T. brucei Cathepsin-L-like Protease

Putative Inhibitor of TcCYP51 from a Library of Approved Drugs: A Virtual Screening Study

High Throughput Screening for Anti–Trypanosoma cruzi Drug Discovery

Novel Diarylthioether Compounds As Agents for the Treatment of Chagas Disease.

Identification of a potent and selective LAPTc inhibitor by RapidFire-Mass Spectrometry, with antichagasic activity

Computer-aided design of 1,4-naphthoquinone-based inhibitors targeting cruzain and rhodesain cysteine proteases

Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi